MDB Capital Holdings, LLC filings document the public-company governance and security structure of a Delaware limited liability company with Class A Common Shares representing limited liability interests listed on the Nasdaq Capital Market under MDBH. Current reports disclose board and audit committee appointments and other material governance events.
Proxy materials describe annual-meeting voting matters, including director elections, auditor ratification and shareholder record-date mechanics. The filings also identify the company’s registered equity class and provide formal disclosure around board composition, committee service and shareholder approval procedures.
MDB Capital Holdings, LLC (MDBH) reported a consolidated net loss of $16.444 million for the three months ended September 30, 2026, compared with $4.657 million a year earlier. For the nine months, consolidated net loss was $32.499 million, versus $19.508 million.
Nine-month fee income was $3.306 million, compared with $2.140 million. Class A loss per share was $1.59 for the quarter and $3.19 for the nine months, versus $0.46 and $1.95 in the corresponding 2025 periods.
The nine-month equity-method loss was $13.225 million and included a $9.856 million impairment charge on the eXoZymes investment. Net cash used in operating activities was $6.697 million, compared with $5.324 million. Cash, cash equivalents and restricted cash totaled $8.747 million at September 30, 2026, versus $15.548 million at December 31, 2025; total assets were $37.492 million at September 30, 2026.
MDB Capital Holdings, LLC (MDBH) CFO Jeremy William James reported converting 10,000 restricted stock units into 10,000 Class A shares on October 26, 2026, on a one-for-one basis; the Class A share acquisition was recorded at $1.55 per share. After the respective transactions, his direct positions were 40,000 RSUs and 39,839 Class A shares. No Rule 10b5-1 plan is reported.
MDB Capital Holdings, LLC director Daniel Thomas Torpey converted 10,000 restricted stock units into 10,000 Class A shares on October 26, 2026, on a one-for-one basis. The Class A share entry lists a price of $1.55 per share. Following the transactions, the RSU row reports 50,000 shares and the Class A share row reports 57,100 directly held shares.
MDB Capital Holdings, LLC director Sean James Magennis reported converting 10,000 restricted stock units into 10,000 Class A shares on October 26, 2026. The Class A acquisition is reported at $1.55 per share. Following the transactions, his reported direct holdings were 40,000 RSUs and 60,000 Class A shares.
Christopher A. Marlett, a co-founder, director and 10% owner of MDB Capital Holdings, LLC (MDBH), directly purchased 917 shares of Common Stock on October 15, 2026, at an average purchase price of $1.93 per share. The shares were bought in multiple transactions priced from $1.87 to $1.93 per share. His reported direct holdings after the purchase were 180,850 shares. No Rule 10b5-1 plan is reported.
MDB Capital Holdings, LLC (MDBH) co-founder, director and ten percent owner Christopher A. Marlett purchased 10,000 shares of common stock at $1.99 per share on October 13, 2026. The shares were held directly, and his reported direct holdings following the purchase were 179,933 shares. No Rule 10b5-1 plan is reported for the purchase.
MDB Capital Holdings, LLC CFO Jeremy William James reported selling 10,000 common shares on October 13, 2026, at $1.99 per share. The sale covered mandatory, non-discretionary tax withholding tied to the vesting of restricted stock grants previously reported. He directly held 29,839 shares after the transaction; no Rule 10b5-1 plan is reported.
MDB Capital Holdings, LLC operates a broker-dealer and intellectual property services platform, with a majority-owned drug development subsidiary and a large equity stake in eXoZymes. As of June 30, 2026, total assets were $50.8 million, down from $63.7 million at December 31, 2025, largely reflecting declines in investment securities and the equity method investment. Liabilities remained low at $1.3 million, leaving total equity of $49.5 million.
For the quarter ended June 30, 2026, MDB reported a net loss attributable to the company of $9.3 million, and a six‑month net loss of $16.1 million, compared with $14.9 million in the prior‑year period. Results were affected by $4.9 million in unrealized losses on broker‑dealer investment securities, a $3.1 million share of eXoZymes’ losses, and a $1.36 million dilution‑related loss. MDB also recorded a $641 thousand impairment on its equity investment in eXoZymes, reducing the carrying value to $33.1 million.
Operating activities used $5.5 million of cash in the first half of 2026, leaving cash, cash equivalents, and segregated cash of $9.9 million at June 30, 2026. The broker‑dealer subsidiary reported net capital of $8.96 million, well above regulatory minimums, and the company has an undrawn $2.0 million revolving credit facility secured by cash, indicating modest leverage but ongoing cash burn.
MDB Capital Holdings, LLC reported a net loss of 6,736 (in thousands) for the three months ended March 31, 2026, compared with a loss of 6,602 (in thousands) a year earlier. Total operating income was 44 (in thousands), as fee income of 2,862 (in thousands) and other income were largely offset by a 3,047 (in thousands) unrealized loss on investment securities at the licensed broker dealer.
General and administrative costs declined to 5,525 (in thousands) from 6,738 (in thousands), mainly from lower compensation. The equity method investment in eXoZymes generated a loss of 1,108 (in thousands), and its carrying amount was 36,339 (in thousands). Total assets were 57,463 (in thousands), and total equity was 56,224 (in thousands). Cash, cash equivalents and restricted cash totaled 12,534 (in thousands), with net cash used in operating activities of 2,945 (in thousands). As of May 14, 2026, 5,438,632 Class A Common Shares were outstanding.
MDB Capital Holdings, LLC director Daniel Thomas Torpey exercised restricted stock units (RSUs) into 20,000 shares of Common Stock. The Form 4 shows this as a derivative exercise, not an open‑market purchase or sale, with total directly held Common Stock rising to 27,100 shares after the transaction.
The filing also reports 80,000 RSUs remaining after this exercise. According to the footnote, each RSU converts into Common Stock on a one‑for‑one basis, meaning these awards function as stock-based compensation rather than cash transactions in the market.